These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3859 related articles for article (PubMed ID: 28521870)

  • 1. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
    Nseir W; Mahamid M
    Curr Atheroscler Rep; 2013 Mar; 15(3):305. PubMed ID: 23328905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under-prescription of statins in patients with non-alcoholic fatty liver disease.
    Del Ben M; Baratta F; Polimeni L; Pastori D; Loffredo L; Averna M; Violi F; Angelico F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 193.